Abstract | BACKGROUND: METHODS: We studied patients from two separate cohorts who were being treated for reflux esophagitis: 72 patients treated with fundoplication in Sweden and 105 treated with omeprazole (20 to 40 mg once daily) in the Netherlands. In both cohorts, the patients were followed for an average of five years (range, three to eight). After fundoplication, the patients did not receive acid-suppressive therapy. The presence of H. pylori was assessed at the first visit by histologic evaluation in the fundoplication group and by histologic and serologic evaluation in the omeprazole group. The patients were not treated for H. pylori infection. Before treatment and during follow-up, the patients underwent repeated gastroscopy, with biopsy sampling for histologic evaluation. RESULTS: CONCLUSIONS:
|
Authors | E J Kuipers, L Lundell, E C Klinkenberg-Knol, N Havu, H P Festen, B Liedman, C B Lamers, J B Jansen, J Dalenback, P Snel, G F Nelis, S G Meuwissen |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 334
Issue 16
Pg. 1018-22
(Apr 18 1996)
ISSN: 0028-4793 [Print] United States |
PMID | 8598839
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Ulcer Agents
- Omeprazole
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Anti-Ulcer Agents
(adverse effects, therapeutic use)
- Cohort Studies
- Esophagitis, Peptic
(complications, microbiology, therapy)
- Female
- Fundoplication
- Gastritis, Atrophic
(etiology)
- Helicobacter Infections
(complications)
- Helicobacter pylori
(isolation & purification)
- Humans
- Male
- Middle Aged
- Omeprazole
(adverse effects, therapeutic use)
|